Findlow Jamie, Lowe Ann, Deane Sarah, Balmer Paul, van den Dobbelsteen Germie, Dawson Maureen, Andrews Nick, Borrow Ray
Vaccine Evaluation Department, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, M13 9WZ, UK.
Vaccine. 2005 Apr 8;23(20):2623-7. doi: 10.1016/j.vaccine.2004.11.029.
Though meningococcal conjugate vaccines are effective against serogroup C, there is currently no vaccine solution for serogroup B disease. PorA outer membrane protein (OMP) is a potential serogroup B vaccine candidate. A hexavalent PorA outer membrane vesicle (OMV) vaccine has been evaluated in phase I and II trials with promising results. However, considerable sequence variation occurs in the variable regions (VRs) encoding these serosubtypes. By using five wild type P1.19,15 variant strains we examined the serum bactericidal antibody (SBA) titres from sera collected from toddlers and school children pre- and post-vaccination. The numbers of subjects with SBA titres of <4, 4 and > or = 8 varied greatly between the different strains. This was also reflected when > or = 4-fold rises in SBA titres were examined. This finding in sera from toddlers and school children may have implications for PorA based vaccines.
尽管脑膜炎球菌结合疫苗对C群有效，但目前尚无针对B群疾病的疫苗解决方案。PorA外膜蛋白（OMP）是B群潜在的疫苗候选物。一种六价PorA外膜囊泡（OMV）疫苗已在I期和II期试验中进行了评估，结果令人鼓舞。然而，编码这些血清亚型的可变区（VRs）存在相当大的序列变异。我们使用5株野生型P1.19,15变异株，检测了接种疫苗前后从幼儿和学龄儿童采集的血清中的血清杀菌抗体（SBA）滴度。不同菌株之间，SBA滴度<4、4以及>或 = 8的受试者数量差异很大。在检测SBA滴度升高>或 = 4倍时也反映出了这一点。在幼儿和学龄儿童血清中的这一发现可能对基于PorA的疫苗有影响。
